Contineum Therapeutics, Inc.CTNMEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class and best-in-class targeted therapies to address unmet medical needs in autoimmune, inflammatory, and fibrotic diseases. It operates across North American and global biotech research networks, advancing multiple pipeline candidates through early to mid-stage clinical trials.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Johnson & Johnson | 10.70% | 2.0M | — | 2024-04-10 |
| Perceptive Advisors LLC | 8.50% | 1.6M | — | 2024-04-15 |
| Nos. of above persons | 5.00% | 950.9K | ▼ -4.30pp | 2024-11-14 |
Insider Transactions
Net 90d: −$227.5K · buys $0 / sells $227.5KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-05-01 | Lorrain Daniel S. | Chief Scientific Officer | Sell (open market) | 3.9K | $13.06 | $50.5K |
| 2026-05-01 | Lorrain Daniel S. | Chief Scientific Officer | Sell (open market) | 300 | $13.84 | $4.2K |
| 2026-04-06 | Lorrain Daniel S. | Chief Scientific Officer | Sell (open market) | 4.2K | $13.43 | $56.0K |
| 2026-03-02 | Lorrain Daniel S. | Chief Scientific Officer | Sell (open market) | 4.2K | $15.01 | $62.6K |
| 2026-03-02 | Tim Watkins | CMO & Head of Development | Option exercise | 3.6K | $4.50 | $16.2K |
| 2026-03-02 | Tim Watkins | CMO & Head of Development | Sell (open market) | 3.6K | $15.02 | $54.2K |
1–6 of 6